Translational Studies on Anti-Atrial Fibrillatory Action of Oseltamivir by its in vivo and in vitro Electropharmacological Analyses

Oseltamivir has been shown to prolong the atrial conduction time and effective refractory period, and to suppress the onset of burst pacing-induced atrial fibrillation in vitro. To better predict its potential clinical benefit as an anti-atrial fibrillatory drug, we performed translational studies b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kambayashi, Ryuichi, Izumi-Nakaseko, Hiroko, Goto, Ai, Tsurudome, Kazuya, Ohshiro, Hironori, Izumi, Taku, Hagiwara-Nagasawa, Mihoko, Chiba, Koki, Nishiyama, Ryota, Oyama, Satomi, Nunoi, Yoshio, Takei, Yoshinori, Matsumoto, Akio, Sugiyama, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118603/
https://www.ncbi.nlm.nih.gov/pubmed/33995006
http://dx.doi.org/10.3389/fphar.2021.593021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118603/
https://www.ncbi.nlm.nih.gov/pubmed/33995006
http://dx.doi.org/10.3389/fphar.2021.593021

Ejemplares similares